Latest news
NewAmsterdam Pharma Wins CHMP Opinion for Obicetrapib Cholesterol Drug - The Clinical Trial VanguardThe Clinical Trial Vanguard · Thu, 06 Aug 2026 06:43:58 GMTNewAmsterdam reports $64.1M Q2 net loss, $678.3M cash; CHMP recommends obicetrapib approval - TradingViewTradingView · Wed, 05 Aug 2026 11:13:00 GMTAmgen’s Repatha receives positive CHMP opinion for broader cardiovascular use - Pharmaceutical Business review -Pharmaceutical Business review - · Thu, 30 Jul 2026 14:31:43 GMTLynavoy recommended for EU approval by the CHMP - PharmaTimesPharmaTimes · Thu, 30 Jul 2026 07:00:00 GMTPOSITIVE CHMP OPINION SUPPORTS BROADER USE OF AMGEN'S REPATHA® BEFORE A FIRST HEART ATTACK OR STROKE - AmgenAmgen · Wed, 29 Jul 2026 07:00:00 GMTCHMP Backs Roche’s Susvimo for Wet AMD, European Commission Decision Pending - eyewire.newseyewire.news · Tue, 28 Jul 2026 18:13:12 GMTNezglyal receives positive CHMP opinion supporting treatment access for boys with cALD - PharmaTimesPharmaTimes · Tue, 28 Jul 2026 10:03:00 GMTWeekly Recap: CHMP negative opinion on arimoclomol and Q2 results call - TradingViewTradingView · Mon, 27 Jul 2026 07:00:00 GMT